Conditions: Menopause Brain Activity Cognition
Keywords: Menopause fMRI Vyvanse
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 18
Healthy volunteers: yes

Brief summary:
This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on executive function and prefrontal cortex activation in menopausal women ages 45-57, who report subjective cognitive difficulties. This protocol will recruit women from Dr. Epperson's ongoing study, Protocol #812470, to examine the impact of LDX on brain activation during performance of cognitive tasks specifically probing prefrontal cortex function.

Detailed description:

Arms:
arm 1: Lisdexamfetamine or Vyvanse arm 2: Placebo pill, capsules

Interventions: intervention 1: Lisdexamfetamine intervention 2: Placebo
Intervention descriptions: intervention 1: The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women. intervention 2: To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.

Protocol document: